Who makes Adenoseine?

Adenoseine is developed by Hospital Nossa Senhora da Conceicao.

What development phase is Adenoseine in?

Adenoseine is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Adenoseine

Hospital Nossa Senhora da Conceicao · FDA-approved active Small molecule Quality 0/100

Adenoseine, marketed by Hospital Nossa Senhora da Conceicao, is a drug with an unspecified mechanism and primary indication, currently generating unknown revenue. The key composition patent for Adenoseine is set to expire in 2028, which may provide a competitive advantage until then. The primary risk is the lack of detailed clinical trial results and competitor information, which could impact market positioning and strategy.

At a glance

Generic name	Adenoseine
Sponsor	Hospital Nossa Senhora da Conceicao
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effect of the Addition of Adenosine on Myocardial Protection During Cardiopulmonary Bypass (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Adenoseine CI brief — competitive landscape report
Adenoseine updates RSS · CI watch RSS
Hospital Nossa Senhora da Conceicao portfolio CI